Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Kidney cancer

PSMA: a potential therapeutic target in RCC

Nature Reviews Urology volume 14, pages 646–647 (2017)Cite this article

Subjects

Prostate-specific membrane antigen (PSMA) is expressed by prostate cancer cells as well as endothelial cells within the neovasculature of a number of malignancies including renal cell carcinoma (RCC). PET radiotracers that target PSMA have shown great promise for imaging RCC. Agents that target PSMA also have the potential to be used as therapeutics in patients with this malignancy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: PSMA expression within the neovasculature of a site of metastatic ccRCC.

References

  1. Chang, S. S. et al. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192–3198 (1999).

    CAS  PubMed  Google Scholar 

  2. Rowe, S. P. et al. PET imaging of prostate-specific membrane antigen in prostate cancer: current state of the art and future challenges. Prostate Cancer Prostatic Dis. 19, 223–230 (2016).

    Article  CAS  Google Scholar 

  3. Kratochwil, C. et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-Labeled PSMA-617. J. Nucl. Med. 57, 1170–1176 (2016).

    Article  CAS  Google Scholar 

  4. Baum, R. P. et al. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J. Nucl. Med. 57, 1006–1013 (2016).

    Article  CAS  Google Scholar 

  5. Baccala, A. et al. Expression of prostate-specific membrane antigen in tumor-associated neovasculature of renal neoplasms. Urology 70, 385–390 (2007).

    Article  Google Scholar 

  6. Rowe, S. P. et al. Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT. Ann. Nucl. Med. 29, 877–882 (2015).

    Article  CAS  Google Scholar 

  7. Sawicki, L. M. et al. Diagnostic potential of PET/CT using a 68Ga-labelled prostate-specific membrane antigen ligand in whole-body staging of renal cell carcinoma: initial experience. Eur. J. Nucl. Med. Mol. Imaging 44, 102–107 (2017).

    Article  CAS  Google Scholar 

  8. Rhee, H. et al. Pilot study: use of gallium-68 PSMA PET for detection of metastatic lesions in patients with renal tumour. EJNMMI Res. 6, 76 (2016).

    Article  Google Scholar 

  9. Spatz, S. et al. Comprehensive evaluation of prostate-specific membrane antigen expression in the vasculature of renal tumors: implications for imaging studies and prognostic role. J Urol. http://dx.doi.org/10.1016/j.juro.2017.08.079 (2017).

  10. Sánchez-Gastaldo, A. et al. Systemic treatment of renal cell cancer: a comprehensive review. Cancer Treat. Rev. 60, 77–89 (2017).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Michael A. Gorin and Steven P. Rowe are at The James Buchanan Brady Urological Institute and Department of Urology, USA; and at The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Baltimore, Maryland 21224, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, Maryland 21287, USA.,

    Michael A. Gorin & Steven P. Rowe

  2. and at The Russell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, 601 North Caroline Street, Baltimore, Maryland 21287, USA.,

    Michael A. Gorin & Steven P. Rowe

Authors
  1. Michael A. Gorin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Steven P. Rowe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael A. Gorin.

Ethics declarations

Competing interests

M.A.G. has served as a consultant to Progenics Pharmaceuticals, the licensee of 18F-DCFPyL. Both authors have received research funding from Progenics Pharmaceuticals.

Related links

FURTHER INFORMATION

OMIM

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gorin, M., Rowe, S. PSMA: a potential therapeutic target in RCC. Nat Rev Urol 14, 646–647 (2017). https://doi.org/10.1038/nrurol.2017.164

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrurol.2017.164

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research